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Raul Altman1* and Claudio Daniel Gonzalez2Abstract
Background: New oral anticoagulant (NOAC) drugs are known to influence the results of some routine hemostasis
tests. Further data are needed to enable routine assessment of the effects of NOAC on clotting parameters in some
special circumstances.
Methods: Following administration of rivaroxaban to patients, at the likely peak and trough activity times, we
assessed the effects on prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), and
clotting time using Russell’s viper venom, and in the presence of phospholipids and calcium reagent available as
DVVreagent® and DVVconfirm®. The data were used to determine an adequate NOAC plasma level based on
anticoagulant activities expressed as a ratio (patients/normal, R-C).
Results: DVVconfirm as R-C could be rapidly performed, and the results were reasonably sensitive for rivaroxaban
and probably for other FX inhibitors. This assay is not influenced by lupus anticoagulant and heparin, does not
require purified NOAC as control, and will measure whole-plasma clotting activity.
Conclusions: We propose a cut-off R-C value of 4.52 ± 0.33 for safety, but clinical studies are needed to establish
whether this cut-off is useful for identifying patients at increased risk of hemorrhage or exhibiting low anticoagulation
effect. It also seems possible that normal R-C could indicate an absence of anticoagulant activity when rivaroxaban is
discontinued due to episodes of uncontrolled bleeding during anticoagulation or for emergency surgery.
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Anticoagulant therapy has well-established benefits, but
also carries the risk of major or fatal bleeding compli-
cations. Furthermore, the beneficial effects of anti-
coagulant therapy are sometimes inadequate, in which
case the loss of protection favors the development of
thromboembolic complications [1]. As alternatives to
heparin (and its congeners) and vitamin K antagonists
(VKAs), novel oral anticoagulants (NOACs) have been
developed for use in preventing venous thrombosis in
surgical patients, or stroke and systemic embolism (SE) in
patients with atrial fibrillation (AF) [2-8]. Several phase 3
trials have shown that NOACs are at least non-inferior to* Correspondence: draltman@arnet.com.ar
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article, unless otherwise stated.low-molecular-weight heparin and to VKAs, but their
clear superiority in terms of overall and vascular mortality
has not consistently been proven.
It has been postulated that NOACs can be given at
fixed doses with no monitoring requirements; however,
some clinical circumstances will still require measurement
of the anticoagulant effect of a NOAC [9,10]. Combining
antiplatelet drugs and warfarin increases the bleeding risk
[11-14]. In situations requiring warfarin and dual anti-
platelet therapy, it is proposed that the level of anticoagu-
lation should be lowered to an international normalized
ratio (INR) of 2.0–2.5 to reduce bleeding risks without af-
fecting therapeutic efficacy [15]. Moreover, investigations
of patients taking two or three medications, including a
NOAC, have shown significant increases in major bleed-
ing [16-18]. Under circumstances where NOACs may in-
crease the risk of bleeding to the extent that it exceeds theCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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assay to accurately measure the drug effect [19,20].
In contrast to warfarin, the anticoagulant effect of
NOACs is difficult to measure. A variety of routine coagu-
lation assays are recommended for assessing drug effects;
however, these tests are not readily available to most clinical
laboratories. Additionally, in vitro study results cannot be
extrapolated to patients due to variable drug concentrations
in the elderly, dependence on renal function, concomitant
use of P-glycoprotein activators or inhibitors, adherence
to treatment, and pharmacodynamic parameters [21-24].
Studies demonstrate poor correlations between drug ef-
fects and assay results, and only limited data are available
regarding the sensitivities of different reagent/instrument
combinations [25-31].
This prospective study was designed to investigate the
use of different commercially available reagents for measur-
ing NOAC coagulation and pharmacodynamic effects, and
to develop an assay for oral anti-factor Xa drugs. The
reagent used in the current study contains Russell’s viper
venom, which directly activates factor X to Factor Xa in the




Twenty-five healthy volunteers (13 women and 12 men)
with no history of thromboembolic or hemorrhagic diseases,
cardiac, renal, hepatic, or malignant diseases, were required
to be drug free for 10 days before the study. Only platelet
poor plasma from subjects with a normal prothrombin
time, activated partial thromboplastin time and thromnin
time that fulfilled the inclusion criteria were used.
Patients
This study included 170 patients receiving prolonged
oral VKA therapy (warfarin or acenocoumarol) who
were referred to our thrombosis center for follow-up
anticoagulant therapy. Data from this patient group were
used to create a reference curve, for comparison with
the DVVconfirm® rate.
The study also included 25 patients who were treated
with the new oral anticoagulant rivaroxaban (15 men, 10
women; mean age, 66.7 ± 16.4 years; median age, 70 years).
These patients had no history of hemorrhagic diseases,
and were referred to our clinic after their own physician
recommended drug use due to deep venous thrombosis
(9 patients), portal vein thrombosis (1 patient), atrial
fibrillation (14 patients), or coronary stenting (1 patient).
All patients were treated with 20 mg rivaroxaban per
day, except for one woman who received 15 mg daily.
Medication was taken at the same hour each morning.
Double antithrombotic (rivaroxaban and aspirin) therapy
was indicated in four patients.Additional medical therapy
Most patients were receiving additional medications at the
time of the study, some of which could influence NOAC
metabolism [22,23], including antidepressants (n = 8),
antidiabetics (n = 1), anxiolytics (n = 10), beta-blockers
(n = 8), ACE inhibitors (n = 8), lipid-lowering agents
(n = 11), protein pump inhibitor (PPI) (n = 6), levothyroxine
(n = 3), diuretics (n = 5), aspirin (n = 4), non-steroidal
anti-inflammatory (n = 2), lanoxin (n = 1), allopurinol
(n = 2), amiodarone (n = 4), and medication for prostatic
hypertrophy (n = 2). No patients were active smokers.
Blood hepatic enzymes and creatinine were assayed.
Serum creatinine levels were below 1.2 mg/mL in all
patients, except one patient who had a creatinine level
of 1.4 mg/mL and a creatinine clearance of 66 mg/minutes.
Patients had to be receiving therapy for ≥7 days before
entering the study.
Hemostasis tests
Venous blood was drawn from the antecubital vein without
stasis, and mixed with 0.11 mol/L sodium citrate (1:10 v/v).
Samples were obtained in the morning for the following
hemostasis studies: prothrombin time (PT), activated par-
tial thromboplastin time (APTT), thrombin time (TT), and
DVV reagent to perform the DVV test and DVVconfirm®
time. The INR reference curve was created using data from
patients with stable INRs and values within the therapeutic
range (2.0–3.5). Samples were not included if a patient
reported being off the assigned therapy within the prior six
weeks. For INR 1.2–1.99 or >3.5, this rule was not applied,
and all samples were incorporated into the analysis.
From the patients taking rivaroxaban, samples were
obtained at the time of peak drug activity after drug in-
gestion (mean, 2.06 ± 0.29 h; median, 2.1 h), and during
the activity trough at 0–2 hours before the next dose
(mean, 23.4 ± 1.09 h; median, 23.5 h). None of the plasma
samples required hematocrit adjustment. Tests were
performed within 3 h of sampling.
Platelet-poor plasma (PPP) was obtained by centrifuging
blood samples at 900 × g for 15 min. Plastic syringes, tubes,
and pipettes were used for all tests. PT, DVVtest®, and
DVVconfirm® were measured in citrated PPP samples using
a coagulometer ST4 (Diagnostica Stago, Asnieres, France).
Prothrombin time was determined using rabbit brain
thromboplastin Neoplastin Plus® (International Sensitivity
Index (ISI) 1.31; Diagnostica Stago, Asnières-sur-Seine,
France). DVVtest® and DVVconfirm® were performed using
the reagents from Sekisui Diagnostics (Stanford, USA) fol-
lowing the manufacturer’s indications. aPTT was measured
using TriniClot aPTT HS reagent (Trinity Biotech, Ireland)
with manual methods at 37°C, according to the manu-
facturer’s instructions.
Thrombin time was measured using a lyophilized prep-
aration containing bovine thrombin (~75 NIH U/mL),





























Figure 1 Agreement between R-PT and R-C in 170 patients
treated with warfarin. (R-PT – RC)/Average% plotted against the
mean of R-PT and RC.
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(Trinity Biotech, Ireland). This powder was diluted follow-
ing the manufacturer’s instructions, and then diluted 1:10
with distilled water to create the working solution. The
diluted thrombin reagent (100 μL) was then preincu-
bated at 37°C and mixed with 100 μL normal or patient
PPP. Normal PPP clotted at around 20 sec, which was
compared with patient plasma.
For comparison between PT, aPTT, TT, DVVtest, and
DVVconfirm, the time coefficients of patients/normal
values were obtained and each expressed as a ratio (R-PT,
R-aPTT, R-TT, R-VV, and R-C, respectively). The means
from the 25 normal donors were used as normal values.
Samples were obtained over three consecutive days, and
were prepared using techniques similar to those used for
preparing patient blood samples. The samples were tested
within three hours of sampling. Reported results are
the means of duplicate assays. Triniclot Factor X (Trinity
Biotech, Ireland) was used as Factor X-deficient plasma.
The lyophilized product was dissolved in distilled water.
Statistical analysis
Quantitative variables are expressed as mean ± SD, and
differences between quantitative data were evaluated by
analysis of variance (ANOVA). Qualitative data are pre-
sented as percentages, and associations between qualitative
data were examined using the Yates-corrected chi-squared
test. Among the patients treated with VKAs, the correlation
between confirm and PT was assessed using the Pearson
method (simple linear model) to obtain the Pearson r
coefficient. The agreement between DVVconfirm and
PT was examined by plotting the difference between
these values against the average of the two values, fol-
lowing the Bland-Altman technique. In patients treated
with rivaroxaban, the differences between DVVconfirm
and other in vitro tests (PT, aPTT, TT, and DVVtest) were
assessed at peak and trough by applying ANOVA and
Scheffe post-hoc tests. Statistical significance was accepted
when p values were below 0.05.
Results
One reference curve was obtained by testing DVVconfirm
in 170 patients receiving stable anticoagulant therapy with
coumadins. The INR a suitable system for minimizing the
reagent variability of different thromboplastins [32] was
used for comparison to evaluate the intensity of anticoa-
gulation. Ratios were calculated (patients/normal, both in
seconds) to determine correlations between the ratio of
INR curves of patients treated with coumadin (R-PT) and
the ratio with DVVconfirm® (R-C). A second reference
curve was obtained by testing a mixture of normal plasma
and factor X-deficient plasma to obtain factor X concen-
trations of between 100% and 1.56%. Then PT, aPTT,
DVVtest, and DVVconfirm times were recorded.Correlation between R-PT and R-C
Warfarin affects the levels of plasma vitamin K-dependent
clotting proteins (indicated by R-PT), and rivaroxaban
inhibits only factor X (indicated by R-C); thus, a direct
relationship between R-PT and R-C is unlikely. Among
the group of 170 patients, the INR varied between 1.22
and 8.38, with R-PT of 1.22 and 5.07, respectively, and
DVVconfirm R-C values between 1.24 and 4.19. Eleven
patients showed INR values of 3.51–8.38 (R-PT, 2.74–5.07),
corresponding to DVVconfirm R-C of 2.95–4.19. Thirty-six
patients had INR values of 1.22–1.99 (R-PT, 1.17–1.67),
corresponding to DVVconfirm R-C of 1.24–1.77. Finally,
123 patients (72.4%) were in the therapeutic INR target
range of 2.0–3.5 (R-PT, 1.68–2.6; R-C, 1.78–2.89). The
Pearson correlation coefficient r for the 170-patient
sample was 0.78 (95% CI, 0.71–0.84; p < 0.001), and the
Spearman correlation coefficient was 0.80 (95% CI,
0.73–0.85; p < 0.001). The linear equation is R-C =
1.0248 + (0.4425 × R-PT). Figure 1 shows the agree-
ment between R-PT and R-C, with the differences be-
tween the two plotted against (R-C + R-PT)/2. As R-C
values were lower than R-PT, the average difference
was displaced 15.6% from 0.
Correlation between concentration of factor X and
clotting test results
A normal reference curve was created using the mean PPP
values of four groups of normal volunteers (n = 5 in each
group) measured on four consecutive days. Normal PPP
was diluted with factor X-deficient plasma to obtain concen-
trations of factor X ranging from 1.56–100% (Table 1).
In each dilution, PT, aPTT, DVVtest, and DVVconfirm
were measured (in seconds) and expressed as a ratio
(diluted PPP/undiluted PPP). TT was not assayed because
Table 1 Influence of factor X concentration on clotting test results
Undiluted Dilution Dilution Dilution Dilution Dilution Dilution p
Test 100% 50% 25% 12.50% 6.25% 3.13% 1.56%
R-PT 1 1.18 ± 0.07 1.42 ± 0.04 1.84 ± 0.14 2.09 ± 0.2 2.71 ± 0.08 3.44 ± 0.25 <0.001
R-aPTT 1 0.99 ± 0.14 1.08 ± 0.11 1.22 ± 0.08 1.3 ± 0.1 1.55 ± 0.26 1.8 ± 0.30 <0.001
R-VV 1 1.13 ± 0.07 1.36 ± 0.07 1.55 ± 0.08 1.85 ± 0.11 2.19 ± 0.24 2.73 ± 0.28 <0.001
R-C 1 1.17 ± 0.11 1.46 ± 0.14 1.79 ± 0.12 2.35 ± 0.16 3.11 ± 0.16 4.52 ± 0.33 <0.001
P 0.034 <0.001 <0.001 <0.001 <0.001 <0.001
Dilution 50%: p < 0.05 for R-aPTT vs. R-PT, R-VV and R-C; Dilution 25%: p < 0.01 for R-aPTT vs. R-PT, R-VV, and R-C; Dilution 12,5%: p < 0.01 for R-aPTT vs. R-PT
and R-C; p < 0.05 for R-aPTT vs. R-VV; p < 0.05 for R-VV vs. R-C and R-PT; Dilution 6.25%: p < 0.01 for R-C vs. R-aPTT; p < 0.05 for R-C vs. R-VV and R-PT; p < 0.01 for
R-PT vs. R-aPTT; p < 0.05 for R-PT vs. R-VV; Dilution 3.13%: p < 0.01 for R-C vs. R-aPTT and R-VV; p < 0.05 for R-C vs. R-PT; p < 0.05 for RaPTT vs. R-VV and R-PT;
Dilution 1.56%: p < 0.01 for R-C vs. R-aPTT, R-VV, and R-PT; p < 0.01 for R-aPTT vs. R-VV and R-PT.
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clotting time using thrombin reagent.
R-C was the most sensitive to factor X concentration,
followed by R-PT using Neoplastin Plus thromboplastin.
R-VV had an intermediate sensibility, and R-aPTT was
only slightly affected by factor X concentration.
Rivaroxaban-treated patients
Twenty-five patients were treated with rivaroxaban. The
dose was 20 mg/day for all patients, except one who
took 15 mg/day. One patient was excluded because he
also took rifampicin, which clearly prevented the effect
of rivaroxaban on clotting parameters. Table 2 includes
data for the 24 remaining patients.
Peak of activity
On average, R-PT was prolonged to 1.7 times the baseline
value (1.72 ± 0.39), and R-aPTT was prolonged 1.3 times
(1.32 ± 0.16). R-TT was slightly modified (1.15 ± 0.16).
The most prolonged values were R-VV (3.08 ± 0.88) and
R-C (3.53 ± 0.68).
Trough of activity
On average, R-PT was prolonged to 1.2 times the baseline
value (1.20 ± 0.12), and R- aPTT and R-TT were slightly
modified (1.08 ± 0.13 and 1.11 ± 0.11, respectively). R-VV
was prolonged more than 1.5 times (1.66 ± 0.37), and R-C
was prolonged nearly 2 times (1.89 ± 0.42).
During both peak and trough activity, RVVtest and
RVVconfirm were the most sensitive to rivaroxaban ac-
tivity. aPTT and TT were only slightly affected by the
anticoagulant capacity of rivaroxaban. In contrast to in
the in vitro factor X concentration curves (Table 1), PT
was found to be slightly modified.
Discussion
An important issue relating to NOAC use is establishing
the therapeutic range and assay used to monitor the anti-
coagulant effect. Clotting assays can be used to estimate
the effects of different concentrations of NOACs spiked
into normal plasma or in the plasma of patients taking thedrugs. The first type of experiment does not account for
the pharmacodynamics of the drug and potential drug
interactions, and thus does not mirror the real situation in
patients treated with NOACs. Moreover, studies in pa-
tients show that the drug concentrations vary during the
day according to their activity peak and short half-life
(peak and trough activities). The current study evaluated
two references curves in comparison with the results
obtained in patients taking rivaroxaban. A reference
curve using the ratio (patient/normal) derived from the
PT of 170 long-term stable patients treated with couma-
dins was compared with the ratio (R-C) obtained in the
same patients using RVVconfirm reagent.
Some previous results suggest that the INR/ISI method
is not suitable for measurement of rivaroxaban and dabi-
gatran [10]. However, Harenberg et al. [33] reported that
in ex vivo studies, STA Neoplastin Plus was the most pre-
cise method for determining the anticoagulant rivaroxa-
ban in human plasma. Thus, we tested this reagent with a
manufacturer-reported ISI of 1.31. PT is affected by the
remaining activity of the so-called vitamin K-dependent
factors, while R-C only indicates the remaining activity of
factor X. In both assays, the end-point is thrombin gener-
ation. As mentioned by Brummel-Ziedins et al. [34], the
thrombin generation profile is not dependent on only one
factor, but on the synergy between all the factors. There-
fore, slight differences in factor levels—all within the nor-
mal range—can lead to large differences in thrombin
generation profiles, and there is unlikely to be a direct re-
lationship between R-PT and R-C concerning the potential
therapeutic and hemorrhagic level.
Normalized prothrombin times obtained with calibrated
thromboplastin and instruments have improved patient
safety in clinical practice. Maintaining INR values of ≥2.0
greatly reduces the incidence of stroke in patients with
atrial fibrillation, and no increase of intracranial bleed-
ing is observed with INR values of less than 4.0 [35].
These findings indicate that an INR between 2.0 and
3.5 (R-PT, 1.68–2.6) is a safe level for preventing stroke
in patients with non-valvular atrial fibrillation, and R-PT
was used as one measure for comparison in this study.
Table 2 Anticoagulation effect of rivaroxaban in 24 patients, measured in PPP using different clotting assays
Peak of activity* in hours Trough of activity** in hours
(mean ± SD, 2.06 ± 0.29) (mean ± SD, 23.4 ± 1.09)
Ratio R-PT R-aPTT R-TT R-VV R-C R-PT R-aPTT R-TT R-VV R-C
Mean 1.72 1.32 1.15 3.08 3.53 1.20 1.08 1.11 1.66 1.89
SD 0.39 0.16 0.16 0.88 0.68 0.12 0.13 0.11 0.37 0.42
Median 1.61 1.28 1.11 2.75 3.53 1.17 1.03 1.2 1.62 1.97
Highest 2.53 1.74 1.67 5.13 5.63 1.46 1.38 1.26 2.35 2.88
Lowest 1.08 1.1 1.0 1.92 2.24 1.04 0.95 0.9 0.86 0.98
*p < 0.01 for R-VV vs. R-PT, R-aPTT, and R-TT; p < 0.01 for R-C vs. R-PT, R-aPTT, and R-TT.
**p < 0.05 for R-C vs. R-PT, R-aPTT, and RTT; p < 0.05 for R-VV vs. R-PT, R-aPTT, and RTT.
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agreement; however, these results differed from those
obtained in patients under rivaroxaban treatment. Patients
with a mean R-PT of 1.72 had an R-C of 3.53 during peak
rivaroxaban activity, and those with a mean R-PT of 1.2
during trough activity had an R-C of 1.89.
A purified fraction of Russell viper venom (RVV-X)
converts FX to the active form of factor X (FXa) [36],
forming the prothrombinase complex. The prothrombinase
complex then activates prothrombin to thrombin, thus
shortening the time of coagulation [37]. We hypothesized
that a readily available reagent containing Russell’s viper
venom (e.g., DVVreagent® and DVVconfirm®), which
directly activates factor X to Factor Xa in the presence
of phospholipids and calcium, could be used to assay re-
sidual thrombin in plasma after the effects of rivaroxa-
ban on FXa, forming thrombin and probably other oral
direct aFX. RVVconfirm has the advantage of not being
influenced by heparin or lupus anticoagulant.
With this in mind, we tested a curve of different factor
X concentrations using PT, aPTT, RVV, and RVVconfirm
to compare the sensitivities of these assays and the levels
of factor X. Our results indicated that RVVconfirm was
most closely correlated with factor X concentration,
followed by PT, and RVVtest, with aPTT being only
slightly sensitive. Comparing these in vitro results with
those obtained in patients under rivaroxaban therapy,
we again found that RVVconfirm was the most sensitive,
followed by RVVtest. Among the other clotting tests in
patients treated with rivaroxaban, TT was not affected,
aPTT was only slightly affected, and PT was barely
affected. The present study did not aim to determine the
drug concentration levels based on the degree of the
anticoagulation effect in plasma of patients treated with
rivaroxaban. However, Tripodi mentioned that the PT
prolongations obtained in his patients were 1.54 times
the baseline, corresponding to 215 ng/mL rivaroxaban in
the plasma from patients taking 20 mg daily [21].
The current study performed assays in each patient
at two different times: two hours after drug ingestion
(peak activity), and close to the time of the next dose(trough activity). For oral anti-Xa drugs, TT was not
sensitive, aPTT was not sensitive enough, and PT was
prolonged but the degree of prolongation was highly
variable with the thromboplastin used in our study.
Tripodi et al. [38] showed that a different expression
of PT results may be better suited for application in
patients taking rivaroxaban.
It has been postulated that NOACs do not require
routine laboratory monitoring due to their predictable
pharmacokinetic and pharmacodynamic profiles. However,
the current study results would indicate a need to monitor
specific coagulation-related processes since R-C value close
to the time of the next dose (trough activity) indicated no
anticoagulant effect in one patient and probably excessive
effect in other after 2 hours of drug ingestion. It is possible
that the present results predict the therapeutic level in
patients treated with rivaroxaban, and perhaps with other
oral direct factor X inhibitors.
Several conclusions can be proposed based on
hemorrhagic accidents in patients with congenital deficit of
factor X. Among such patients, Brown and Kouides [39]
proposed classification of severity based on FX:C activity
measurements, with FX:C < 1% being severe, 1–5% being
moderate, and 6–10% being mild. Bleeding is infrequent in
patients with Factor X levels above 20%, while patients with
FX levels < 10% present with mucocutaneous bleeding and
those with moderate–severe deficiency may have symp-
toms, including hemarthrosis, intracranial hemorrhage, and
gastrointestinal bleeding. These patients experience spon-
taneous bleeding when their plasma concentration of factor
X is below 1% [40-43], and could also bleed with higher
levels in a traumatic situation.
In the curves created with different Factor X concentra-
tions, 1.56% factor X corresponded to an R-C of 4.52 ± 0.33,
which we consider to be the measurement limit. None of
the patients had renal dysfunction, but their clotting profile
R-C varied between 5.63 and 2.24 at peak activity, and be-
tween 2.88 and 0.98 in the trough. Their R-VV profile varied
between 5.13 and 1.92 at peak activity, and between 2.35
and 0.86 in the trough. In contrast, R-PT was slightly sensi-
tive, and R-aPTT and R-TT were not sensitive enough to
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DVVconfirm test in 24 patients, one had an R-C above the
theoretical point of safety (mean + SD; R-C 4.52 ± 0.33) at
the peak of treatment. However, the efficacy limit cannot be
deduced from the present study. It is also important to
consider the safety data regarding the potential risk-benefit
assessment of antithrombotic therapy, particularly in cases
where dual and triple antithrombotic regimens are necessary
in elderly patients [44].
One of the first concerns regarding NOACs was the
lack of an antidote. Although an antidote for factor Xa
inhibitors has now entered phase 2 studies in normal
volunteers, there remains a need for an assay of drug
activity. Our results in patients taking rivaroxaban
demonstrated that at the activity peak where PT, aPTT,
and TT were normal, R-VV and R-C were prolonged,
likely indicating an adequate anticoagulation level.
During the activity trough, most PT, aPTT, and TT
values were normal or close to normal. In contrast,
one patient showed no anticoagulant activity using
RVVconfirm (R-V, 0.98), and low activity was indicated
in three patients (R-C, 1.35, 1.47, and 1.58) whereas
adequated anticoagulant effect were obtained in the
other 20 patients. Similar results were obtained with
RVVtest: three patients showed no anticoagulant effect
(R-VV, 0.86, 1.1, and 1.16) and three patients exhibited
likely low rivaroxaban activity (R-VV, 1.29, 1.32, and
1.38). Thus, it seems possible that R-C and R-VV can
indicate the lack of rivaroxaban activity when drug use
is discontinued due to episodes of uncontrolled bleed-
ing during anticoagulation or for emergency surgery.
Conclusions
In conclusion, we believe that dose adjustment based on
therapeutic effect may be more appropriate than fixed-
dose therapy but clinical trials are needed to support this
recommendation. Laboratories should determine the
sensitivity of their methods to the presence of NOAC. In
spite of the available body of information, most current
recommendations are based on the interpretations and
opinions of experts.
It has been postulated that the rivaroxaban dose must
be reduced in patients with impaired renal function ac-
cording to creatinine clearance. However available assays
do not account for drug interactions and, although cre-
atinine clearance is easy to perform and Cockcroft-Gault
equation can be used to estimate creatinine clearance
for purposes of NOAC dosing the possible assay fre-
quency depends on the patient’s clinical condition and
adherence. Here we found that the R-C results were rea-
sonably sensitive for rivaroxaban and likely also sensitive
for other FX inhibitors. This assay can be performed rap-
idly, is not influenced by lupus anticoagulant and heparin,does not require a purified NOAC as a control, and mea-
sures whole-plasma clotting activity. Clinical studies are
needed to establish definite cut-off values for R-C, and to
determine whether they are useful for identifying patients
at increased risk of hemorrhage or with low prevention
effect. Additionally, patient adherence to therapy is of
utmost importance.
Addendum
A small group of patients were treated with dabigatran
therapy (150 or 110 mg every 12 h; 4 patients in each
group) using experimental conditions similar to those
described in the current paper. The results suggest that
DVVconfirm using R-C data is also sensitive to the
anticoagulation effect of dabigatran.
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